BLUEBIRD BIO INC (BLUE) Stock News

Top movers analysis one hour before the close of the markets on 2025-02-21: top gainers and losers in today's session.

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Mentions: AXTI TXMD GLOB WINT ...

Top movers in Friday's session

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Mentions: AXTI TXMD GLOB WINT ...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.

/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by bluebird bio, Inc. (NASDAQ: BLUE) and its board of directors concerning...

Mentions: CG

Dow Tumbles Over 700 Points; US Services PMI Falls In February

Mentions: UPC GDEV BURU MNDR ...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Mentions: VOXX CARA CYTH

Gapping stocks in Friday's session

The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Mentions: INOD AXTI ACCO GLOB ...

Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders

BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders

These stocks are moving in today's pre-market session

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Mentions: NCL AXTI UE DOYU ...

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

Mentions: CG

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

bluebird bio Announces 1-for-20 Reverse Stock Split

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Exploring bluebird bio's Earnings Expectations

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Mentions: PFE AGIO CRSP BEAM ...

Bluebird Bio to Cut 25% of Staff Amid Gene Therapy Struggles

Bluebird Bio Inc. announced plans to cut about a quarter of its workforce as the biotech confronts a difficult environment for companies that make gene therapies, costly one-time treatments for hard-to-treat conditions.

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

bluebird bio Announces September Investor Events

bluebird bio Announces Receipt of Expected Notices from Nasdaq